A device designed to capture more TAVR procedural debris proves noninferior to an existing device in a large trial, but the ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...

Emboline's Emboliner system excels in a global trial, showing superior debris capture and procedural success in TAVR patients ...

Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H ...

NEW YORK, NY—Use of a cerebral embolic protection device (EPD) during TAVI may prevent disabling strokes, but any effect appears to be modest, according to an updated analysis of the Society of ...

Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US ...

SANTA CRUZ, Calif., March 11, 2026 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

The recall was initiated following reports of 9 device malfunctions. Cardiovascular Systems Inc. has issued a voluntary recall of unused WIRION ® Embolic Protection systems due to complaints of filter ...

The Sentinel cerebral embolic protection (CEP) device failed to reduce the overall stroke rate in patients undergoing transcatheter aortic valve replacement (TAVR) in the largest TAVR trial to date, ...